Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BeOne Medicines, the BeOne Care Foundation, and The Max Foundation have extended their partnership to expand Brukinsa (zanubrutinib) access for chronic lymphocytic leukaemia (CLL) treatment in low- and middle-income countries until 2028.
The initiative aims to improve access to CLL therapy in regions where advanced treatments are unavailable. Credit: evan_huang / Shutterstock.com.
Subscribe to our email newsletter
The renewed agreement is expected to reach approximately 1,000 patients cumulatively by its conclusion.
This partnership, which began in 2023, has so far provided Brukinsa to more than 300 CLL patients in Armenia, Ethiopia, and Nepal. The figure surpassed the programme’s initial goal by around 150 patients.
The initiative is aimed at improving access to CLL therapy in regions where advanced treatments have previously been limited or unavailable.
Support for the project involves donated Brukinsa from BeOne Medicines and a $1m BeOne Care Foundation grant, which together help underpin patient care, physician involvement, and operational needs for the next two years.
The Max Foundation leads implementation efforts based on its experience with oncology access programmes.
BeOne Medicines co-founder, chairman and CEO John Oyler said: “From the beginning, our goal has been to ensure that where a person lives does not determine whether they can access high-quality cancer care.
“Renewing this partnership with The Max Foundation reflects both the impact we have already achieved together and our commitment to reaching many more patients who otherwise may have limited treatment options.”
The agreement will maintain support in Armenia, Ethiopia, and Nepal, and may include additional countries such as Côte d’Ivoire, Malawi, Mongolia, Mozambique, Togo, and Zambia, depending on future capacity and priorities.
The model includes provisions for ongoing treatment for enrolled patients beyond 2028 if clinically required.
Earlier this month, BeOne Medicines signed a multi-part collaboration with Revolution Medicines to develop and commercialise targeted oncology therapies.
